2018 Q4 Form 10-Q Financial Statement
#000106282218000036 Filed on November 01, 2018
Income Statement
| Concept | 2018 Q4 | 2018 Q3 | 2017 Q4 |
|---|---|---|---|
| Revenue | $17.07M | $6.966M | $33.97M |
| YoY Change | -49.74% | -74.83% | 47.44% |
| Cost Of Revenue | $600.0K | $551.0K | $500.0K |
| YoY Change | 20.0% | -8.01% | |
| Gross Profit | $16.80M | $6.415M | $33.90M |
| YoY Change | -50.44% | -76.31% | |
| Gross Profit Margin | 98.41% | 92.09% | 99.81% |
| Selling, General & Admin | $16.60M | $15.60M | $16.00M |
| YoY Change | 3.75% | -6.72% | 13.48% |
| % of Gross Profit | 98.81% | 243.18% | 47.2% |
| Research & Development | $12.10M | $13.76M | $42.60M |
| YoY Change | -71.6% | -64.83% | 62.6% |
| % of Gross Profit | 72.02% | 214.54% | 125.66% |
| Depreciation & Amortization | $900.0K | $900.0K | $900.0K |
| YoY Change | 0.0% | 0.0% | 50.0% |
| % of Gross Profit | 5.36% | 14.03% | 2.65% |
| Operating Expenses | $28.60M | $29.89M | $58.60M |
| YoY Change | -51.19% | -47.05% | 45.41% |
| Operating Profit | -$12.37M | -$22.93M | -$29.02M |
| YoY Change | -57.38% | -19.85% | -7.39% |
| Interest Expense | -$5.200M | $5.252M | -$2.200M |
| YoY Change | 136.36% | 224.4% | 37.5% |
| % of Operating Profit | |||
| Other Income/Expense, Net | $800.0K | $783.0K | $600.0K |
| YoY Change | 33.33% | 88.67% | 20.0% |
| Pretax Income | -$16.30M | -$27.40M | -$26.30M |
| YoY Change | -38.02% | -10.83% | 17.41% |
| Income Tax | $0.00 | $0.00 | $0.00 |
| % Of Pretax Income | |||
| Net Earnings | -$16.78M | -$27.40M | -$26.61M |
| YoY Change | -36.93% | -8.09% | -17.92% |
| Net Earnings / Revenue | -98.31% | -393.28% | -78.34% |
| Basic Earnings Per Share | -$0.26 | ||
| Diluted Earnings Per Share | -$153.9K | -$0.26 | -$211.2K |
| COMMON SHARES | |||
| Basic Shares Outstanding | 105.9M shares | 105.9M shares | 105.6M shares |
| Diluted Shares Outstanding | 105.9M shares |
Balance Sheet
| Concept | 2018 Q4 | 2018 Q3 | 2017 Q4 |
|---|---|---|---|
| SHORT-TERM ASSETS | |||
| Cash & Short-Term Investments | $160.1M | $187.3M | $310.8M |
| YoY Change | -48.49% | -4.83% | -10.3% |
| Cash & Equivalents | $80.39M | $48.90M | $61.66M |
| Short-Term Investments | $79.70M | $138.4M | $249.1M |
| Other Short-Term Assets | $2.668M | $3.395M | $4.434M |
| YoY Change | -39.83% | -23.84% | 14.34% |
| Inventory | $4.680M | $4.755M | $1.948M |
| Prepaid Expenses | |||
| Receivables | $5.924M | $2.913M | $4.825M |
| Other Receivables | $0.00 | $0.00 | $0.00 |
| Total Short-Term Assets | $173.3M | $198.4M | $322.0M |
| YoY Change | -46.17% | -7.32% | -10.03% |
| LONG-TERM ASSETS | |||
| Property, Plant & Equipment | $15.87M | $16.30M | $17.69M |
| YoY Change | -10.3% | -10.28% | -8.78% |
| Goodwill | $44.54M | $44.54M | $44.54M |
| YoY Change | 0.0% | 0.0% | 0.0% |
| Intangibles | $50.12M | $50.56M | $51.89M |
| YoY Change | -3.4% | -3.37% | -2.76% |
| Long-Term Investments | |||
| YoY Change | |||
| Other Assets | $285.0K | $429.0K | $429.0K |
| YoY Change | -33.57% | 0.0% | -6.94% |
| Total Long-Term Assets | $110.8M | $111.8M | $114.5M |
| YoY Change | -3.26% | -3.15% | -2.72% |
| TOTAL ASSETS | |||
| Total Short-Term Assets | $173.3M | $198.4M | $322.0M |
| Total Long-Term Assets | $110.8M | $111.8M | $114.5M |
| Total Assets | $284.1M | $310.2M | $436.5M |
| YoY Change | -34.91% | -5.86% | -8.22% |
| SHORT-TERM LIABILITIES | |||
| YoY Change | |||
| Accounts Payable | $12.05M | $51.48M | $38.76M |
| YoY Change | -68.91% | -2.18% | -26.69% |
| Accrued Expenses | $21.25M | $13.79M | $12.28M |
| YoY Change | 72.98% | 8.37% | -61.75% |
| Deferred Revenue | |||
| YoY Change | |||
| Short-Term Debt | $0.00 | $0.00 | $0.00 |
| YoY Change | |||
| Long-Term Debt Due | $1.115M | $1.115M | $14.09M |
| YoY Change | -92.09% | -92.38% | -13.43% |
| Total Short-Term Liabilities | $36.75M | $68.51M | $105.5M |
| YoY Change | -65.16% | -46.78% | -35.93% |
| LONG-TERM LIABILITIES | |||
| Long-Term Debt | $243.9M | $243.8M | $231.6M |
| YoY Change | 5.32% | 185.14% | 171.91% |
| Other Long-Term Liabilities | $238.0K | $252.0K | $292.0K |
| YoY Change | -18.49% | -16.83% | -63.73% |
| Total Long-Term Liabilities | $244.1M | $244.1M | $231.9M |
| YoY Change | 5.29% | 184.43% | 169.7% |
| TOTAL LIABILITIES | |||
| Total Short-Term Liabilities | $36.75M | $68.51M | $105.5M |
| Total Long-Term Liabilities | $244.1M | $244.1M | $231.9M |
| Total Liabilities | $310.5M | $339.6M | $368.3M |
| YoY Change | -15.68% | 35.24% | 15.73% |
| SHAREHOLDERS EQUITY | |||
| Retained Earnings | -$1.472B | -$1.471B | -$1.365B |
| YoY Change | 7.79% | 8.76% | 9.19% |
| Common Stock | $106.0K | $106.0K | $106.0K |
| YoY Change | 0.0% | 0.0% | 0.95% |
| Preferred Stock | |||
| YoY Change | |||
| Treasury Stock (at cost) | $2.876M | $2.876M | $1.904M |
| YoY Change | 51.05% | 51.05% | -43.47% |
| Treasury Stock Shares | 236.0K shares | 236.0K shares | 122.0K shares |
| Shareholders Equity | -$26.41M | -$29.40M | $68.27M |
| YoY Change | |||
| Total Liabilities & Shareholders Equity | $284.1M | $310.2M | $436.5M |
| YoY Change | -34.91% | -5.86% | -8.22% |
Cashflow Statement
| Concept | 2018 Q4 | 2018 Q3 | 2017 Q4 |
|---|---|---|---|
| OPERATING ACTIVITIES | |||
| Net Income | -$16.78M | -$27.40M | -$26.61M |
| YoY Change | -36.93% | -8.09% | -17.92% |
| Depreciation, Depletion And Amortization | $900.0K | $900.0K | $900.0K |
| YoY Change | 0.0% | 0.0% | 50.0% |
| Cash From Operating Activities | -$27.10M | -$22.20M | -$33.70M |
| YoY Change | -19.58% | -34.71% | -30.94% |
| INVESTING ACTIVITIES | |||
| Capital Expenditures | $0.00 | $0.00 | $0.00 |
| YoY Change | -100.0% | ||
| Acquisitions | |||
| YoY Change | |||
| Other Investing Activities | $58.80M | $56.40M | -$135.7M |
| YoY Change | -143.33% | -35.25% | -339.75% |
| Cash From Investing Activities | $58.80M | $56.40M | -$135.8M |
| YoY Change | -143.3% | -35.25% | -340.35% |
| FINANCING ACTIVITIES | |||
| Cash Dividend Paid | |||
| YoY Change | |||
| Common Stock Issuance & Retirement, Net | |||
| YoY Change | |||
| Debt Paid & Issued, Net | |||
| YoY Change | |||
| Cash From Financing Activities | -100.0K | -400.0K | 147.8M |
| YoY Change | -100.07% | -20.0% | 73800.0% |
| NET CHANGE | |||
| Cash From Operating Activities | -27.10M | -22.20M | -33.70M |
| Cash From Investing Activities | 58.80M | 56.40M | -135.8M |
| Cash From Financing Activities | -100.0K | -400.0K | 147.8M |
| Net Change In Cash | 31.60M | 33.80M | -21.70M |
| YoY Change | -245.62% | -35.74% | -374.68% |
| FREE CASH FLOW | |||
| Cash From Operating Activities | -$27.10M | -$22.20M | -$33.70M |
| Capital Expenditures | $0.00 | $0.00 | $0.00 |
| Free Cash Flow | -$27.10M | -$22.20M | -$33.70M |
| YoY Change | -19.58% | -34.71% | -30.8% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| dei |
Entity Small Business
EntitySmallBusiness
|
false | ||
| dei |
Entity Registrant Name
EntityRegistrantName
|
LEXICON PHARMACEUTICALS, INC./DE | ||
| dei |
Document Type
DocumentType
|
10-Q | ||
| dei |
Entity Central Index Key
EntityCentralIndexKey
|
0001062822 | ||
| CY2018Q4 | dei |
Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
|
105925402 | shares |
| dei |
Entity Current Reporting Status
EntityCurrentReportingStatus
|
Yes | ||
| dei |
Entity Emerging Growth Company
EntityEmergingGrowthCompany
|
false | ||
| dei |
Entity Filer Category
EntityFilerCategory
|
Large Accelerated Filer | ||
| dei |
Amendment Flag
AmendmentFlag
|
false | ||
| dei |
Current Fiscal Year End Date
CurrentFiscalYearEndDate
|
--12-31 | ||
| dei |
Document Fiscal Period Focus
DocumentFiscalPeriodFocus
|
Q3 | ||
| dei |
Document Fiscal Year Focus
DocumentFiscalYearFocus
|
2018 | ||
| dei |
Document Period End Date
DocumentPeriodEndDate
|
2018-09-30 | ||
| CY2018Q3 | lxrx |
Buildings Collateral
BuildingsCollateral
|
59200000 | USD |
| CY2017Q3 | lxrx |
Change In Fair Value Of Symphony Icon Inc Purchase Liability
ChangeInFairValueOfSymphonyIconIncPurchaseLiability
|
0 | USD |
| lxrx |
Change In Fair Value Of Symphony Icon Inc Purchase Liability
ChangeInFairValueOfSymphonyIconIncPurchaseLiability
|
2101000 | USD | |
| CY2018Q3 | lxrx |
Change In Fair Value Of Symphony Icon Inc Purchase Liability
ChangeInFairValueOfSymphonyIconIncPurchaseLiability
|
0 | USD |
| lxrx |
Change In Fair Value Of Symphony Icon Inc Purchase Liability
ChangeInFairValueOfSymphonyIconIncPurchaseLiability
|
0 | USD | |
| CY2014Q4 | lxrx |
Conv Debt Instrument Interest Rate Stated Percentage
ConvDebtInstrumentInterestRateStatedPercentage
|
0.0525 | |
| CY2017Q4 | lxrx |
Deferred Tax Assetremeasured
DeferredTaxAssetremeasured
|
171400000 | USD |
| CY2007Q2 | lxrx |
Holdings Contribution To Icon
HoldingsContributionToIcon
|
45000000 | USD |
| lxrx |
Ipsen Maximum Regulatory And Commercial Milestones
IpsenMaximumRegulatoryAndCommercialMilestones
|
13000000 | USD | |
| CY2014Q4 | lxrx |
Ipsen Maximum Sales Milestones
IpsenMaximumSalesMilestones
|
72000000 | EUR |
| CY2016Q3 | lxrx |
Ipsen Milestone Payment
IpsenMilestonePayment
|
6400000 | USD |
| lxrx |
Ipsen Milestone Payment
IpsenMilestonePayment
|
6400000 | USD | |
| lxrx |
Ipsen Milestone Payment
IpsenMilestonePayment
|
5100000 | USD | |
| CY2017Q4 | lxrx |
Ipsen Milestone Payment Received
IpsenMilestonePaymentReceived
|
3840000 | USD |
| CY2017Q4 | lxrx |
Ipsen Milestone Payment Received
IpsenMilestonePaymentReceived
|
3840000 | USD |
| CY2017Q3 | lxrx |
Ipsen Milestone Payment Received
IpsenMilestonePaymentReceived
|
5100000 | USD |
| lxrx |
Ipsen Product Revenue
IpsenProductRevenue
|
800000 | USD | |
| lxrx |
Ipsen Product Revenue
IpsenProductRevenue
|
1400000 | USD | |
| CY2014Q4 | lxrx |
Ipsen Revenue Allocatedto Committee Deliverable
IpsenRevenueAllocatedtoCommitteeDeliverable
|
100000 | USD |
| CY2014Q4 | lxrx |
Ipsen Revenue Allocatedto Development Deliverable
IpsenRevenueAllocatedtoDevelopmentDeliverable
|
1700000 | USD |
| CY2014 | lxrx |
Ipsen Revenue Allocatedto License Deliverable
IpsenRevenueAllocatedtoLicenseDeliverable
|
21200000 | USD |
| CY2015 | lxrx |
Ipsen Revenue Allocatedto License Deliverable
IpsenRevenueAllocatedtoLicenseDeliverable
|
1400000 | USD |
| lxrx |
Ipsen Revenue Recognized
IpsenRevenueRecognized
|
7900000 | USD | |
| lxrx |
Ipsen Revenue Recognized
IpsenRevenueRecognized
|
2200000 | USD | |
| CY2018Q3 | lxrx |
Ipsen Total Payments
IpsenTotalPayments
|
43700000 | USD |
| CY2015Q1 | lxrx |
Ipsen Total Upfront Payments
IpsenTotalUpfrontPayments
|
24500000 | USD |
| CY2018Q3 | lxrx |
Land Collateral
LandCollateral
|
2700000 | USD |
| CY2010Q3 | lxrx |
Lexicon Paid Holdings Cash
LexiconPaidHoldingsCash
|
10000000 | USD |
| CY2007Q2 | lxrx |
Lexicon Received Cash From Holdings
LexiconReceivedCashFromHoldings
|
15000000 | USD |
| CY2007Q2 | lxrx |
Lexicon Sold Shares To Holdings
LexiconSoldSharesToHoldings
|
1092946 | shares |
| CY2018Q3 | lxrx |
Mortgage Debt Instrument Revere Lxrx
MortgageDebtInstrument_Revere_LXRX
|
12400000 | USD |
| CY2018Q3 | lxrx |
Mortgage Debt Issue Costs Revere Lxrx
MortgageDebtIssueCosts_Revere_LXRX
|
400000 | USD |
| CY2017Q3 | lxrx |
Netproductrevenue
Netproductrevenue
|
5830000 | USD |
| lxrx |
Netproductrevenue
Netproductrevenue
|
10443000 | USD | |
| CY2018Q3 | lxrx |
Netproductrevenue
Netproductrevenue
|
6286000 | USD |
| lxrx |
Netproductrevenue
Netproductrevenue
|
19062000 | USD | |
| CY2015Q4 | lxrx |
Sanofi Commercialization Costs Fundedby Lexicon Maximum Amount
SanofiCommercializationCostsFundedbyLexiconMaximumAmount
|
100000000 | USD |
| CY2015Q4 | lxrx |
Sanofi Development Milestones
SanofiDevelopmentMilestones
|
110000000 | USD |
| CY2015Q4 | lxrx |
Sanofi Outcomes Study Milestone
SanofiOutcomesStudyMilestone
|
100000000 | USD |
| CY2015Q4 | lxrx |
Sanofi Regulatory Milestones
SanofiRegulatoryMilestones
|
220000000 | USD |
| CY2015Q4 | lxrx |
Sanofi Revenue Allocatedto Development Deliverable
SanofiRevenueAllocatedtoDevelopmentDeliverable
|
113800000 | USD |
| CY2015Q4 | lxrx |
Sanofi Revenue Allocatedto Funding Deliverable
SanofiRevenueAllocatedtoFundingDeliverable
|
59400000 | USD |
| CY2015Q4 | lxrx |
Sanofi Revenue Allocatedto License Deliverable
SanofiRevenueAllocatedtoLicenseDeliverable
|
126800000 | USD |
| lxrx |
Sanofi Revenue Recognized
SanofiRevenueRecognized
|
39500000 | USD | |
| lxrx |
Sanofi Revenue Recognized
SanofiRevenueRecognized
|
25300000 | USD | |
| CY2015Q4 | lxrx |
Sanofi Sales Milestone Payments
SanofiSalesMilestonePayments
|
990000000 | USD |
| CY2015Q4 | lxrx |
Sanofi Upfront Payment
SanofiUpfrontPayment
|
300000000 | USD |
| CY2017Q3 | lxrx |
Sellinggeneralandadministrativeexpenses
Sellinggeneralandadministrativeexpenses
|
16724000 | USD |
| lxrx |
Sellinggeneralandadministrativeexpenses
Sellinggeneralandadministrativeexpenses
|
50069000 | USD | |
| CY2018Q3 | lxrx |
Sellinggeneralandadministrativeexpenses
Sellinggeneralandadministrativeexpenses
|
15579000 | USD |
| lxrx |
Sellinggeneralandadministrativeexpenses
Sellinggeneralandadministrativeexpenses
|
47191000 | USD | |
| lxrx |
Share Based Compensation Arrangementby Sharebased Payment Award Equity Instructions Other Than Options Vested Immediately Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementbySharebasedPaymentAwardEquityInstructionsOtherThanOptionsVestedImmediatelyWeightedAverageGrantDateFairValue
|
7.80 | ||
| lxrx |
Sharebased Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Granted In Periodto Board
SharebasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodtoBoard
|
20512 | shares | |
| lxrx |
Shares Issued To Symphony Designees Value
SharesIssuedToSymphonyDesigneesValue
|
10499000 | USD | |
| lxrx |
Shares Issued To Symphony Designees Value
SharesIssuedToSymphonyDesigneesValue
|
0 | USD | |
| CY2017Q3 | lxrx |
Stock Based Compensation Expense Associated With Research And Development Expense
StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense
|
1345000 | USD |
| lxrx |
Stock Based Compensation Expense Associated With Research And Development Expense
StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense
|
3698000 | USD | |
| CY2018Q3 | lxrx |
Stock Based Compensation Expense Associated With Research And Development Expense
StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense
|
1472000 | USD |
| lxrx |
Stock Based Compensation Expense Associated With Research And Development Expense
StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense
|
4522000 | USD | |
| CY2017Q3 | lxrx |
Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense
Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense
|
1235000 | USD |
| lxrx |
Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense
Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense
|
3516000 | USD | |
| CY2018Q3 | lxrx |
Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense
Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense
|
1405000 | USD |
| lxrx |
Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense
Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense
|
4327000 | USD | |
| CY2010Q3 | lxrx |
Symphon Fair Value Of Base And Contingent Payments
SymphonFairValueOfBaseAndContingentPayments
|
45600000 | USD |
| CY2016Q3 | lxrx |
Symphony Amendment Buyout
SymphonyAmendmentBuyout
|
21000000 | USD |
| CY2010Q3 | lxrx |
Symphony Base Payment Discount Rate
SymphonyBasePaymentDiscountRate
|
0.14 | |
| CY2012Q3 | lxrx |
Symphony Base Payment In Shares
SymphonyBasePaymentInShares
|
1891074 | shares |
| CY2012Q3 | lxrx |
Symphony Base Payment Obligation
SymphonyBasePaymentObligation
|
35000000 | USD |
| CY2010Q3 | lxrx |
Symphony Contingent Payment Discount Rate
SymphonyContingentPaymentDiscountRate
|
0.18 | |
| CY2014Q4 | lxrx |
Symphony Contingent Payment In Cash
SymphonyContingentPaymentInCash
|
5800000 | USD |
| CY2015Q2 | lxrx |
Symphony Contingent Payment In Cash
SymphonyContingentPaymentInCash
|
750000 | USD |
| CY2016Q3 | lxrx |
Symphony Contingent Payment In Cash
SymphonyContingentPaymentInCash
|
3200000 | USD |
| CY2017Q1 | lxrx |
Symphony Contingent Payment In Cash
SymphonyContingentPaymentInCash
|
10500000 | USD |
| CY2010Q3 | lxrx |
Symphony Contingent Payment Maximum
SymphonyContingentPaymentMaximum
|
45000000 | USD |
| CY2010Q3 | lxrx |
Symphony Contingent Payment Percentage
SymphonyContingentPaymentPercentage
|
0.50 | |
| CY2014Q4 | lxrx |
Symphony Contingent Payment Total
SymphonyContingentPaymentTotal
|
11500000 | USD |
| CY2014Q4 | lxrx |
Symphony Contingent Paymentin Shares
SymphonyContingentPaymentinShares
|
666111 | shares |
| CY2017Q1 | lxrx |
Symphony Contingent Paymentin Shares
SymphonyContingentPaymentinShares
|
659905 | shares |
| CY2010Q3 | lxrx |
Symphony Payment In Stock Limitation
SymphonyPaymentInStockLimitation
|
0.50 | |
| CY2010Q3 | lxrx |
Symphony Regulatory Approval Payment
SymphonyRegulatoryApprovalPayment
|
15000000 | USD |
| CY2010Q3 | lxrx |
Symphony Regulatory Approval Percentage Limit
SymphonyRegulatoryApprovalPercentageLimit
|
0.50 | |
| CY2010Q3 | lxrx |
Symphony Regulatory Approval Reduction Percentage
SymphonyRegulatoryApprovalReductionPercentage
|
0.50 | |
| lxrx |
Xermelo Intangible Assets Finite Lived
XERMELOIntangibleAssetsFiniteLived
|
24700000 | USD | |
| CY2017Q4 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
57652000 | USD |
| CY2018Q3 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
51480000 | USD |
| CY2017Q4 | us-gaap |
Accounts Receivable Net Current
AccountsReceivableNetCurrent
|
4825000 | USD |
| CY2018Q3 | us-gaap |
Accounts Receivable Net Current
AccountsReceivableNetCurrent
|
2913000 | USD |
| CY2017Q4 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
12282000 | USD |
| CY2018Q3 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
13794000 | USD |
| CY2017Q4 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
58623000 | USD |
| CY2018Q3 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
59936000 | USD |
| CY2017Q4 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
-222000 | USD |
| CY2018Q3 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
-71000 | USD |
| CY2017Q4 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
1435526000 | USD |
| CY2018Q3 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
1444925000 | USD |
| us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
7214000 | USD | |
| us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
8849000 | USD | |
| CY2017Q4 | us-gaap |
Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
|
4000 | USD |
| CY2018Q3 | us-gaap |
Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
|
4000 | USD |
| us-gaap |
Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
|
412000 | USD | |
| us-gaap |
Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
|
957000 | USD | |
| us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
1000000 | USD | |
| us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
1300000 | USD | |
| us-gaap |
Asset Impairment Charges
AssetImpairmentCharges
|
0 | USD | |
| us-gaap |
Asset Impairment Charges
AssetImpairmentCharges
|
0 | USD | |
| us-gaap |
Asset Impairment Charges
AssetImpairmentCharges
|
0 | USD | |
| us-gaap |
Asset Impairment Charges
AssetImpairmentCharges
|
0 | USD | |
| CY2017Q4 | us-gaap |
Assets
Assets
|
436539000 | USD |
| CY2018Q3 | us-gaap |
Assets
Assets
|
310192000 | USD |
| CY2017Q4 | us-gaap |
Assets Current
AssetsCurrent
|
321995000 | USD |
| CY2018Q3 | us-gaap |
Assets Current
AssetsCurrent
|
198360000 | USD |
| CY2017Q4 | us-gaap |
Available For Sale Securities
AvailableForSaleSecurities
|
249127000 | USD |
| CY2018Q3 | us-gaap |
Available For Sale Securities
AvailableForSaleSecurities
|
138395000 | USD |
| CY2016Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
46600000 | USD |
| CY2017Q3 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
83293000 | USD |
| CY2017Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
61661000 | USD |
| CY2014Q4 | us-gaap |
Debt Instrument Convertible Conversion Ratio1
DebtInstrumentConvertibleConversionRatio1
|
118.4553 | |
| CY2017Q4 | us-gaap |
Debt Instrument Description
DebtInstrumentDescription
|
200000000 | |
| CY2018Q3 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
48902000 | USD |
| CY2017Q4 | us-gaap |
Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
|
61661000 | USD |
| CY2018Q3 | us-gaap |
Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
|
48902000 | USD |
| us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
36693000 | USD | |
| us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
-12759000 | USD | |
| CY2017Q4 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
USD | |
| CY2018Q3 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
USD | |
| CY2017Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
| CY2018Q3 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
| CY2017Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
225000000 | shares |
| CY2018Q3 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
225000000 | shares |
| CY2017Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
106000 | USD |
| CY2018Q3 | us-gaap |
Common Stock Value
CommonStockValue
|
106000 | USD |
| CY2017Q3 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-30571000 | USD |
| us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-100540000 | USD | |
| CY2018Q3 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-27365000 | USD |
| us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-104142000 | USD | |
| CY2017Q3 | us-gaap |
Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
|
599000 | USD |
| us-gaap |
Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
|
1361000 | USD | |
| CY2018Q3 | us-gaap |
Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
|
551000 | USD |
| us-gaap |
Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
|
1922000 | USD | |
| CY2014Q4 | us-gaap |
Debt Instrument Convertible Conversion Price1
DebtInstrumentConvertibleConversionPrice1
|
8.442 | |
| CY2017Q4 | us-gaap |
Debt Instrument Face Amount
DebtInstrumentFaceAmount
|
150000000 | USD |
| CY2018Q3 | us-gaap |
Debt Instrument Fair Value
DebtInstrumentFairValue
|
130900000 | USD |
| CY2018Q3 | us-gaap |
Debt Instrument Interest Rate Stated Percentage
DebtInstrumentInterestRateStatedPercentage
|
0.0900 | |
| CY2018Q3 | us-gaap |
Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
|
3400000 | USD |
| CY2017Q3 | us-gaap |
Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
|
0 | USD |
| us-gaap |
Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
|
-8652000 | USD | |
| CY2018Q3 | us-gaap |
Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
|
0 | USD |
| us-gaap |
Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
|
0 | USD | |
| CY2017Q4 | us-gaap |
Deferred Finance Costs Gross
DeferredFinanceCostsGross
|
4100000 | USD |
| us-gaap |
Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
|
-8652000 | USD | |
| us-gaap |
Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
|
0 | USD | |
| CY2017Q4 | us-gaap |
Deferred Revenue Current
DeferredRevenueCurrent
|
40099000 | USD |
| CY2018Q3 | us-gaap |
Deferred Revenue Current
DeferredRevenueCurrent
|
2117000 | USD |
| CY2017Q4 | us-gaap |
Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
|
22428000 | USD |
| CY2018Q3 | us-gaap |
Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
|
20991000 | USD |
| CY2017Q4 | us-gaap |
Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
|
6014000 | USD |
| CY2018Q3 | us-gaap |
Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
|
6014000 | USD |
| us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
2475000 | USD | |
| us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
2771000 | USD | |
| CY2017Q3 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.29 | |
| us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.96 | ||
| CY2018Q3 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.26 | |
| us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.99 | ||
| us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
|
2101000 | USD | |
| CY2017Q4 | us-gaap |
Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
|
1471000 | USD |
| CY2018Q3 | us-gaap |
Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
|
2795000 | USD |
| us-gaap |
Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
|
-2000 | USD | |
| us-gaap |
Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
|
0 | USD | |
| CY2017Q4 | us-gaap |
Goodwill
Goodwill
|
44543000 | USD |
| CY2018Q3 | us-gaap |
Goodwill
Goodwill
|
44543000 | USD |
| CY2018Q3 | us-gaap |
Guarantee Obligations Maximum Exposure
GuaranteeObligationsMaximumExposure
|
2700000 | USD |
| CY2017Q3 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-30722000 | USD |
| us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-109324000 | USD | |
| CY2018Q3 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-27512000 | USD |
| us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-104293000 | USD | |
| us-gaap |
Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
-11738000 | USD | |
| us-gaap |
Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
-4700000 | USD | |
| us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
3105000 | USD | |
| us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
-1912000 | USD | |
| us-gaap |
Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
|
-37023000 | USD | |
| us-gaap |
Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
|
-25207000 | USD | |
| us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
2149000 | USD | |
| us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
2807000 | USD | |
| us-gaap |
Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
|
-32000 | USD | |
| us-gaap |
Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
|
0 | USD | |
| us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
580000 | USD | |
| us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
-1039000 | USD | |
| CY2018Q3 | us-gaap |
Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
|
50561000 | USD |
| CY2017Q4 | us-gaap |
Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
|
51885000 | USD |
| CY2017Q4 | us-gaap |
Inventory Gross
InventoryGross
|
1948000 | USD |
| CY2018Q3 | us-gaap |
Inventory Gross
InventoryGross
|
4755000 | USD |
| CY2017Q3 | us-gaap |
Interest Expense
InterestExpense
|
1619000 | USD |
| us-gaap |
Interest Expense
InterestExpense
|
4821000 | USD | |
| CY2018Q3 | us-gaap |
Interest Expense
InterestExpense
|
5252000 | USD |
| us-gaap |
Interest Expense
InterestExpense
|
15553000 | USD | |
| us-gaap |
Interest Paid Net
InterestPaidNet
|
3272000 | USD | |
| us-gaap |
Interest Paid Net
InterestPaidNet
|
10470000 | USD | |
| CY2017Q4 | us-gaap |
Inventory Finished Goods
InventoryFinishedGoods
|
1183000 | USD |
| CY2018Q3 | us-gaap |
Inventory Finished Goods
InventoryFinishedGoods
|
975000 | USD |
| CY2017Q4 | us-gaap |
Inventory Net
InventoryNet
|
1948000 | USD |
| CY2018Q3 | us-gaap |
Inventory Net
InventoryNet
|
4755000 | USD |
| CY2017Q4 | us-gaap |
Inventory Raw Materials
InventoryRawMaterials
|
616000 | USD |
| CY2018Q3 | us-gaap |
Inventory Raw Materials
InventoryRawMaterials
|
3598000 | USD |
| CY2017Q4 | us-gaap |
Inventory Work In Process
InventoryWorkInProcess
|
149000 | USD |
| CY2018Q3 | us-gaap |
Inventory Work In Process
InventoryWorkInProcess
|
182000 | USD |
| CY2017Q4 | us-gaap |
Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
|
310788000 | USD |
| CY2018Q3 | us-gaap |
Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
|
187297000 | USD |
| CY2017Q4 | us-gaap |
Liabilities
Liabilities
|
384437000 | USD |
| CY2018Q3 | us-gaap |
Liabilities
Liabilities
|
339593000 | USD |
| CY2017Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
436539000 | USD |
| CY2018Q3 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
310192000 | USD |
| CY2017Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
124127000 | USD |
| CY2018Q3 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
68506000 | USD |
| CY2017Q4 | us-gaap |
Long Term Debt Current
LongTermDebtCurrent
|
14094000 | USD |
| CY2018Q3 | us-gaap |
Long Term Debt Current
LongTermDebtCurrent
|
1115000 | USD |
| CY2017Q4 | us-gaap |
Long Term Debt Noncurrent
LongTermDebtNoncurrent
|
231576000 | USD |
| CY2018Q3 | us-gaap |
Long Term Debt Noncurrent
LongTermDebtNoncurrent
|
243830000 | USD |
| us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
2088000 | USD | |
| us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
-2105000 | USD | |
| us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
186288000 | USD | |
| us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
110825000 | USD | |
| us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-151683000 | USD | |
| us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-121479000 | USD | |
| CY2017Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-30722000 | USD |
| us-gaap |
Net Income Loss
NetIncomeLoss
|
-100672000 | USD | |
| CY2018Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-27512000 | USD |
| us-gaap |
Net Income Loss
NetIncomeLoss
|
-104293000 | USD | |
| us-gaap |
New Accounting Pronouncement Or Change In Accounting Principle Effect Of Adoption Quantification
NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification
|
0 | USD | |
| us-gaap |
New Accounting Pronouncement Or Change In Accounting Principle Effect Of Adoption Quantification
NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification
|
14212000 | USD | |
| CY2017Q3 | us-gaap |
Operating Expenses
OperatingExpenses
|
56460000 | USD |
| us-gaap |
Operating Expenses
OperatingExpenses
|
163184000 | USD | |
| CY2018Q3 | us-gaap |
Operating Expenses
OperatingExpenses
|
29899000 | USD |
| us-gaap |
Operating Expenses
OperatingExpenses
|
137254000 | USD | |
| CY2017Q3 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-29518000 | USD |
| us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
1393000 | USD | |
| CY2017Q4 | us-gaap |
Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
|
292000 | USD |
| CY2018Q3 | us-gaap |
Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
|
252000 | USD |
| CY2017Q3 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
415000 | USD |
| us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-105896000 | USD | |
| CY2018Q3 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-23043000 | USD |
| us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-91438000 | USD | |
| CY2017Q4 | us-gaap |
Other Assets Current
OtherAssetsCurrent
|
4434000 | USD |
| CY2018Q3 | us-gaap |
Other Assets Current
OtherAssetsCurrent
|
3395000 | USD |
| CY2017Q4 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
429000 | USD |
| CY2018Q3 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
429000 | USD |
| CY2017Q3 | us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
|
151000 | USD |
| us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
|
132000 | USD | |
| CY2018Q3 | us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
|
147000 | USD |
| us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
|
151000 | USD | |
| CY2018Q3 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
783000 | USD |
| us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
2698000 | USD | |
| CY2014Q4 | us-gaap |
Payment Of Financing And Stock Issuance Costs
PaymentOfFinancingAndStockIssuanceCosts
|
3400000 | USD |
| us-gaap |
Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
|
1679000 | USD | |
| us-gaap |
Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
|
972000 | USD | |
| us-gaap |
Payments To Acquire Investments
PaymentsToAcquireInvestments
|
59237000 | USD | |
| us-gaap |
Payments To Acquire Investments
PaymentsToAcquireInvestments
|
84475000 | USD | |
| us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
224000 | USD | |
| us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
58000 | USD | |
| CY2017Q4 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.01 | |
| CY2018Q3 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.01 | |
| CY2017Q4 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
5000000 | shares |
| CY2018Q3 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
5000000 | shares |
| CY2017Q4 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | shares |
| CY2018Q3 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | shares |
| CY2017Q4 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | shares |
| CY2018Q3 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | shares |
| CY2017Q4 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
0 | USD |
| CY2018Q3 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
0 | USD |
| CY2014Q4 | us-gaap |
Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
|
87500000 | USD |
| us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
5481000 | USD | |
| us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
550000 | USD | |
| us-gaap |
Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
|
0 | USD | |
| us-gaap |
Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
|
12529000 | USD | |
| us-gaap |
Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
|
245749000 | USD | |
| us-gaap |
Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
|
195358000 | USD | |
| CY2017Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
17687000 | USD |
| CY2018Q3 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
16299000 | USD |
| us-gaap |
Realized Investment Gains Losses
RealizedInvestmentGainsLosses
|
-7000 | USD | |
| us-gaap |
Realized Investment Gains Losses
RealizedInvestmentGainsLosses
|
0 | USD | |
| us-gaap |
Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
|
1714000 | USD | |
| us-gaap |
Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
|
14212000 | USD | |
| CY2017Q3 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
39137000 | USD |
| CY2017Q3 | us-gaap |
Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
|
21112000 | USD |
| us-gaap |
Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
|
46781000 | USD | |
| CY2018Q3 | us-gaap |
Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
|
446000 | USD |
| us-gaap |
Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
|
26470000 | USD | |
| CY2017Q3 | us-gaap |
Revenues
Revenues
|
26942000 | USD |
| us-gaap |
Revenues
Revenues
|
57288000 | USD | |
| CY2018Q3 | us-gaap |
Revenues
Revenues
|
6856000 | USD |
| us-gaap |
Revenues
Revenues
|
45816000 | USD | |
| CY2017Q3 | us-gaap |
Royalty Income Nonoperating
RoyaltyIncomeNonoperating
|
0 | USD |
| us-gaap |
Royalty Income Nonoperating
RoyaltyIncomeNonoperating
|
64000 | USD | |
| us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
109653000 | USD | |
| CY2018Q3 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
13769000 | USD |
| us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
88141000 | USD | |
| CY2017Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-1381404000 | USD |
| CY2018Q3 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-1471485000 | USD |
| CY2018Q3 | us-gaap |
Royalty Income Nonoperating
RoyaltyIncomeNonoperating
|
124000 | USD |
| us-gaap |
Royalty Income Nonoperating
RoyaltyIncomeNonoperating
|
284000 | USD | |
| us-gaap |
Share Based Compensation
ShareBasedCompensation
|
7214000 | USD | |
| us-gaap |
Share Based Compensation
ShareBasedCompensation
|
8849000 | USD | |
| CY2017Q4 | us-gaap |
Short Term Investments
ShortTermInvestments
|
249127000 | USD |
| CY2018Q3 | us-gaap |
Short Term Investments
ShortTermInvestments
|
138395000 | USD |
| us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
5481000 | USD | |
| us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
550000 | USD | |
| us-gaap |
Stock Issued During Period Value Treasury Stock Reissued
StockIssuedDuringPeriodValueTreasuryStockReissued
|
0 | USD | |
| CY2017Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
52102000 | USD |
| CY2018Q3 | us-gaap |
Stockholders Equity
StockholdersEquity
|
-29401000 | USD |
| CY2016Q4 | us-gaap |
Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
|
157401000 | USD |
| CY2017Q3 | us-gaap |
Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
|
78376000 | USD |
| CY2017Q4 | us-gaap |
Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
|
52102000 | USD |
| CY2018Q3 | us-gaap |
Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
|
-29401000 | USD |
| CY2017Q4 | us-gaap |
Treasury Stock Shares
TreasuryStockShares
|
122000 | shares |
| CY2018Q3 | us-gaap |
Treasury Stock Shares
TreasuryStockShares
|
236000 | shares |
| CY2017Q4 | us-gaap |
Treasury Stock Value
TreasuryStockValue
|
1904000 | USD |
| CY2018Q3 | us-gaap |
Treasury Stock Value
TreasuryStockValue
|
2876000 | USD |
| us-gaap |
Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
|
1679000 | USD | |
| us-gaap |
Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
|
972000 | USD | |
| CY2018Q3 | us-gaap |
Unamortized Debt Issuance Expense
UnamortizedDebtIssuanceExpense
|
1500000 | USD |
| us-gaap |
Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
|
132000 | USD | |
| us-gaap |
Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
|
151000 | USD | |
| CY2017Q3 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
105582000 | shares |
| us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
105119000 | shares | |
| CY2018Q3 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
105881000 | shares |
| us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
105800000 | shares | |
| us-gaap |
Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
|
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Concentration of Credit Risk:</font><font style="font-family:inherit;font-size:10pt;"> Lexicon’s cash equivalents, investments and accounts receivable represent potential concentrations of credit risk. The Company attempts to minimize potential concentrations of risk in cash equivalents and investments by placing investments in high-quality financial instruments. The Company’s accounts receivable are unsecured and are concentrated in pharmaceutical and biotechnology companies located in Europe and the United States.  The Company has not experienced any significant credit losses to date.  </font></div></div> | ||
| us-gaap |
Use Of Estimates
UseOfEstimates
|
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Use of Estimates:</font><font style="font-family:inherit;font-size:10pt;"> The preparation of financial statements in conformity with U. S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates.</font></div></div> |
